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CatL is essential for proteinuric kidney diseases. (A) Quantitative rt-
PCR of microdissected glomeruli from human biopsies of patients with 
acquired proteinuric diseases: minimal change disease (MCD; n = 7), 
membranous glomerulonephritis (MGN; n = 9), focal segmental glo-
merulosclerosis (FSGS; n = 7), and diabetic nephropathy (DN; n = 10). 
**P < 0.01. CON, control (n = 8). (B) CatL labeling of normal human 
kidney. (C) CatL labeling of human kidney with diabetic nephropathy, 
mildly reduced renal function, and nephrotic range proteinuria. (D) 
Immunocytochemistry of mouse glomeruli using monoclonal anti-CatL 
antibody. WT mice received either PBS (WT CON) or LPS (WT LPS). 
LPS was also injected into CatL–/– mice (CatL–/– LPS). Original magni-
fication, ×400 (C and D). (E) Electron micrographs of FPs. (F) Urinary 
protein levels determined using the standard Bradford protein assay. 
Urine was collected immediately before (Baseline) and 48 hours after 
addition of LPS. Each bar represents at least 8 animals.
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Induction of cytoplasmic CatL protein and activity by LPS. (A) Cultured podocytes were stained using anti–LAMP-2 antibodies and the BIOMOL 
CV-CatL/B activity detection kit. Control cells, cells treated with 50 μg/ml of LPS for 24 hours, and cells treated with LPS and 1 μM of the selective 
CatL inhibitor Z-FF-FMK are shown. (B) Labeling of cultured podocytes using anti-CatL antibody, untreated or after treatment with 50 μg/ml of 
LPS for 24 hours. (C) Labeling of cultured podocytes using anti-CatB antibody, untreated or after treatment with 50 μg/ml of LPS for 24 hours. 
(D) Schematic of CatL mRNA and resulting proteins. (E) Subcellular fractionation of podocytes in isotonic sucrose prior to and 24 hours after 
LPS treatment. Total proteins from the soluble (S) and the particulate (P) fractions were analyzed by Western blotting.
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CatL cleaves dynamin:GTP in vitro and in vivo. If dynamin is a CatL 
target in the cytoplasm, then recombinant dynamin should be 
cleavable by CatL at neutral pH. The PEPS algorithm identified 


















Altered dynamin staining in glomerulus after LPS treatment is CatL dependent. (A) Immunogold analysis of dynamin in podocyte FPs of rat 
glomerulus. Low-power view (left) depicts dynamin within the center of podocyte FPs (asterisk) as well as in electron-dense areas rich of 
cortical actin (a) (original magnification, ×30,000). High-power view shows gold particles, which are associated with the cytoplasmic side of 
vesicles (v) and with electron-dense actin areas (a) (original magnification, ×45,000). E, endosome; GBM, glomerular basement membrane; 
Ly, lysosome; SD, slit diaphragm; US, urinary space. (B) Immunocytochemistry of dynamin in glomeruli of WT mice before and after injec-
tion of LPS and of CatL–/– mice after injection of LPS. (C) Immunocytochemistry of samples from CatL–/– mice for glomerular dynamin and 
CatL. CatL–/– mice had been reconstituted with either Pre-Pro-CatL (left) or with short CatL (right) using transient gene transfer. Twenty-four 
hours after gene transfer, glomeruli were stained using anti-CatL and anti-dynamin hudy 1 antibody. Original magnification, ×400 (B and 
C). (D) Immunoblot of endogenous dynamin in cultured podocytes in response to LPS. Recombinant dynamin (REC), extracts of WT and 
CatL–/– podocytes, were analyzed. (E) Quantitation of dynamin in cell extracts shown in D. Dynamin signal was adjusted to actin levels.
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Effects of the nucleotide-bound and assembly state of dynamin on CatL cleavage in vitro and in vivo. (A) Domain structure of dynamin, correspond-
ing antibodies, and amino acid sequence of predicted CatL cleavage sites. Note that the ELSGGA sequence is a highly conserved motif throughout 
the species. PH, pleckstrin homology domain; PRD, proline-arginine rich domain; Shi, dynamin homolog in Drosophila; Vsp1, dynamin homolog 
in yeast. (B) Schematic depiction of dynamin GTPase cycle. In its basal state, dynamin is a homotetramer. Self-assembly into higher-order struc-
tures such as rings or spirals can be promoted by GTPϒS and activates assembly-mediated GTP hydrolysis, which in turn drives disassembly. 
Dynamin’s middle domain is located inside the spiral. (C) Recombinant dyn1 (20 pmol) (CON) was mixed with CatL (1 pmol) (top panel), CatB 
(middle panel), or Furin (bottom panel). The reactions were performed at pH 7.0 under nonassembly conditions (200 mM NaCl). Where indicated, 
200 μM GTP or 1 mM GTPϒS was present. Proteolytic products were detected by monoclonal anti-dynamin antibody against the GTPase domain. 
(D) Silver staining of recombinant dyn1 incubated with CatL at different pHs in the presence or absence of GTPϒS. (E) Western blot analysis using 
GTPase antibody of podocyte extracts infected with various dynamin mutants before or after addition of 100 μg/ml LPS for 20 hours. Note the 
appearance of a 40-kDa fragment (arrow). When indicated, podocytes were treated with 1 μM of the selective CatL inhibitor Z-FF-FMK for the dura-
tion of the LPS treatment. (F) Western blot analysis of subcellular fractionation of podocytes expressing dynWT for 24 hours after LPS treatment. 
Extracts were blotted using antibodies against the GTPase domain (N-terminal), GAP domain (C-terminal), LAMP-2, and tubulin.
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LPS-induced dynamin cleavage in mouse kidneys. (A–C) Double immunofluorescence of dyn1 (MAB-5402 antibody; red) and the podocyte 
marker synaptopodin (green). Mice were injected with podocin-driven expression vector lacking the dynamin gene (A), CMV-dyn1 expression 
vector (B), and POD-dyn1 expression vector (C). Western blot analysis of total kidney and liver extracts isolated from animals injected with dif-
ferent cDNAs as indicated in the figure. (D) Immunocytochemistry of glomeruli from mice that were injected with LPS. Twenty-four hours after 
LPS injections, animals received cDNA expressing dynWT, dynL356Q, and dynR725A and were sacrificed 14 hours later. Glomeruli were stained using 
monoclonal anti-dynamin hudy 1 antibody. Original magnification, ×400 (A–D). (E) Western blot analysis of kidney extracts after gene delivery 
of different dyn1 cDNAs using the GTPase and CatL antibody before and after addition of LPS.
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Dynamin is required for normal glomerular function. The hypothesis 
that cleavage of dynamin by CatL leads to proteinuria implies that 
Figure 6
The effects of dynamin mutants 
on proteinuria and podocyte mor-
phology. (A) Urinary protein levels 
determined using the standard 
Bradford protein assay. Urine was 
collected immediately before (0 h) 
and 14 and 24 hours after injection 
of podocin-driven expression vec-
tors containing different dynamin 
constructs as indicated in the fig-
ure. Each bar represents at least 
10 animals. (B) Cultured podo-
cytes were infected with adeno-
viruses expressing the indicated 
dynamin constructs. Eighteen 
hours after infection, cells were 
stained with hudy 1 (green) to visu-
alize dynamin and rhodamine phal-
loidin (red) to visualize F-actin. (C) 
Urinary protein levels determined 
using the standard Bradford pro-
tein assay. Mice were injected at 
0 and 24 hours with LPS to induce 
proteinuria. At 48 hours (peak 
proteinuria), mice received empty 
vector, CMV-dynWT, CMV-dynL356Q, 
or CMV-dynR725A. Urinary protein 
levels were determined 12 hours 
after injection. Each data point 
represents at least 10 animals. (D) 
Urinary protein levels determined 
using the standard Bradford pro-
tein assay. Mice were injected at 
0 and 24 hours with LPS to induce 
proteinuria. At 48 hours (peak pro-
teinuria), mice received empty vec-
tor, POD-dynWT, POD-dynL356Q, or 
POD-dynR725A. Urinary protein lev-
els were determined 12 hours after 
injection. Each bar represents at 
least 10 animals.
research article




























































































































































































































































































































































ment  results  in  Src  kinase  activation,  nephrin 
phosphorylation,  Nck  recruitment,  and  actin 
polymerization.  J. Clin. Invest.  116:1346–1359. 
doi:10.1172/JCI27414.
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